Regeneron Pharmaceuticals and Sanofi are paying $67.5 million to improve the chances of getting their experimental cholesterol-lowering drug on the market before any other drug company with similar cholesterol treatments in development. Regeneron and Sanofi are purchasing a first-of-its-kind voucher that grants expedited review by drug regulators, paving the way for faster Food and Drug Administration (FDA) approval. The voucher was awarded to BioMarin Pharmaceuticals as an incentive for drug companies to invest in drugs for rare childhood diseases. It allows the drug company expedited review of a different drug of its choice. Companies given vouchers can also sell them ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.